Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - November 2012

Stability Testing in Pharmaceutical Development and Manufacturing (2 day)

21 Nov 2012 - 22 Nov 2012 - Window Conference Venue, 13 Windsor Street, Islington, London, N1 8QG

Bookmark and Share

Course objectives
New and important techniques in stability testing are facilitating product development using the
Quality by Design approach.  Using these it is possible to develop products more quickly and
reliably, through improved methods of shelf life prediction and excipient testing.  New stability
testing protocols using the published ASAP method from Pfizer can generate information quickly and reliably. The purpose of this course is to give a comprehensive, integrated overview of pharmaceutical stability testing in a highly interactive, relaxed environment: 

• Why is stability testing required for product registration and GMP purposes?
• What are the requirements for Clinical Trials, new, and existing products?
• How can stability testing be applied during product development to shorten development times as well as improve product quality
• Stability testing outsourcing - successful management and execution

It will include:
• A comprehensive review of ICH stability testing guidance ICH Q1A
• Pitfalls in stability testing.  Outsourcing—costs and benefits
• New approaches to stability testing including ASAP  and the role of peroxides in product
• Stability Testing and QbD
• Workshops for attendees to present and discuss their own stability testing issues with the group 

Who will benefit:
The course is designed for people working in:
• Analytical and Product Development 
• Analytical Chemistry
• Stability Testing 
• Formulation Development 
• Regulatory Affairs 
• Pharmaceutical & Biopharmaceutical Production 
• Quality Control and Quality Assurance
• Technical Operations 

Course Programme
Day 1
The course will commence at 8.30 with registration and coffee, course proper will commence at 9.00 and finish at 5.00pm each day
• The life cycle approach to product development and Quality by Design
• Stability testing in product development
• ICH Q6 – specifications, and how to set them.  Role of specifications in stability testing.  Alternative approaches to deriving specifications
• ICH Guidance Q1A (R2) – a comprehensive review
• Case study 
“Effect of Processing and Formulation Variables on the stability of a salt of a weakly basic drug candidate (tablet)” – Badawy et al, BMS
• EU GMP guidance on stability testing
• Evaluation of stability data – ICH guidance Q1E.  Identifying out of trend data.  Alternative approaches.
• Data interpretation case studies including attendee problems
• Bracketing and matrixing designs for stability testing of new drug substances and products - ISC Q1E
• Photostability testing—Q1B
• Action Planning and Final Q&A
Workshop and examples based on delegate’s interests
Group discussion, problem solving and consultancy
 Additional Resources
Online access to comprehensive publications including all relevant guidance will be provided as well as colour copies of all presentations and case studies .                                             
Dr Michael Gamlen is Managing Director of Pharmaceutical Development Services Ltd, 
a pharmaceutical consultancy based in Nottingham (UK).  Dr Gamlen has over 30 years 
experience of tablet development. Awarded a First Class Honours degree in Pharmacy, 
specialising in Pharmaceutical Engineering, he studied for a PhD at Nottingham University.  
He was Head of Tablet Development at the The Wellcome Foundation for 15 years, and
worked as an outsourcing manager before starting his consultancy business in 2000. 
Dr Gamlen specialises in managing product development, formulation, tablet and process 
development studies.  He has been teaching professional tabletting courses for many years and
his courses are highly rated, exceeding the expectation of the participants in many cases.
Michael continually updates the content of his courses with the latest guidance and   extracts of up-to-the minute scientific papers.  
He provides a substantial body of relevant literature to all course participants  as well as copies of all notes and guidance used and a workbook.  He is a   popular and highly respected presenter.

Further information
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos